Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile.

Region Region Suzhou
  Country China
Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 Suzhou Hybiome Biomedical Engineering Co. Ltd.
  Group Mérieux (Group)
Product Product  immunoassay (diagnostics, antibody-antigen-test)
Index term Index term Hybiome (CN)–Mérieux: investment, 201807–201811 acquisition 54% shareholding in Suzhou Hybiome Biomedical Engineering Co Ltd by bioMérieux
Persons Person Morgeau, Sylvain (Mérieux 201602 Investor Relations at bioMérieux)
  Person 2 Heilbronn, Laurence (Image Sept 201405 Partner + Consultant)

bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier announcement of the acquisition of a majority stake in this company in November 2018.

Founded in 2009 and located in Suzhou (China), Hybiome is specialized in automated immunoassay tests. The company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments and software) cleared by the National Medical Products Administration (NMPA). In Q1 2019, Hybiome successfully continued to develop its commercial reach into the rapidly growing Grade 2 hospital market.

An additional 13% stake has been acquired for about 20 million euros. Following this transaction, bioMérieux now holds 67% of the shares of Hybiome.


The Mérieux family has developed close ties with China spanning three generations. Today China holds an important position in the strategy of bioMérieux:
> 2nd largest bioMérieux subsidiary in terms of revenue
> 6 offices: Shanghai, Beijing, Chengdu, Guangzhou, Suzhou, Hong Kong and Taipei

In addition, the Company is committed to promoting educational programs for healthcare professionals, with a focus on the medical and economic value of diagnostics and initiatives to raise awareness about major public health challenges, such as antimicrobial resistance.


Pioneering Diagnostics A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 43 countries and serves more than 160 countries with the support of a large network of distributors. In 2018, revenues reached €2.4 billion, with over 90% of international sales.

bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. Its diagnostic solutions are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website:
Investor website:


Investor Relations

Sylvain Morgeau
Tel.: + 33 4 78 87 22 37

Media Relations

Aurore Sergeant
Tel.: + 33 4 78 87 20 53

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
Claire Doligez
Tel.: +33 (0)1 53 70 74 48

Record changed: 2023-06-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Mérieux (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top